La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

HOOKIPA Pharma Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Malte Peters

Amministratore delegato

US$232.3k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	1.5yrs
Durata media del Consiglio di amministrazione	3.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%

Aug 13

Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge

Jun 22

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

Apr 28

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Mar 24

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

Aug 11

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

May 16

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Apr 26

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Nov 19

HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy

Jul 25

Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts

May 18

Hookipa: Speculative Biotech With Key Catalysts In 2022

Mar 29

AMMINISTRATORE DELEGATO

Malte Peters (62 yo)

less than a year

Mandato

US$232,306

Compensazione

Dr. Malte Peters, MD., is Director at HOOKIPA Pharma Inc. since 2023 and is its Chief Executive Officer since July 22, 2024 and served as its Ad Interim Senior Clinical Advisor from September 2023 until Ma...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Malte Peters	CEO & Director	less than a year	US$232.31k	Nessun dato
Mary Coelho	Executive VP	less than a year	US$85.88k	0% $ 0
Rolf Zinkernagel	Co-Founder	13.6yrs	Nessun dato	Nessun dato
Andreas Bergthaler	Co-Founder	13.6yrs	Nessun dato	Nessun dato
Lukas Flatz	Co-Founder	13.6yrs	Nessun dato	Nessun dato
Roman Necina	Chief Operations Officer	less than a year	Nessun dato	Nessun dato
Klaus Orlinger	Chief Scientific Officer	2.4yrs	Nessun dato	Nessun dato
Matthew L. Beck	Executive Director of Investor Relations	no data	Nessun dato	Nessun dato
Michael Szumera	Executive Director of Communications	no data	Nessun dato	Nessun dato
Mark Winderlich	Chief Development Officer	less than a year	Nessun dato	Nessun dato
Daniel Courtney	Corporate Secretary	no data	Nessun dato	Nessun dato

1.5yrs

Durata media

59yo

Età media

Gestione esperta: Il team dirigenziale di HOOK non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Malte Peters	CEO & Director	1.6yrs	US$232.31k	Nessun dato
Mary Coelho	Executive VP	1.3yrs	US$85.88k	0% $ 0
Jan G.J. de Winkel	Independent Chairman of the Board	7.6yrs	US$127.98k	0.0076% $ 4.6k
Sander Van Deventer	Scientific Advisory Member	4.2yrs	US$23.76k	Nessun dato
Sean Cassidy	Director	less than a year	Nessun dato	Nessun dato
Julie O'Neill	Independent Non-Executive Director	5.8yrs	US$67.74k	0.0041% $ 2.5k
David Kaufman	Independent Director	5.3yrs	US$71.74k	0.0038% $ 2.3k
Timothy Reilly	Independent Non-Executive Director	2.3yrs	US$71.74k	0% $ 0

3.3yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HOOK sono considerati esperti (durata media dell'incarico 3.3 anni).

HOOKIPA Pharma Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

HOOKIPA Pharma Inc. Announces CFO Changes

HOOKIPA Pharma Inc., Annual General Meeting, Jun 17, 2024

HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024

HOOKIPA Pharma Inc. Announces Appointment of Dr. Roman Necina as Chief Operations Officer, Effective January 1, 2024

HOOKIPA Pharma Inc. Announces Resignation of Christine Baker as Chief Operating Officer, Leaving on January 15, 2024

HOOKIPA Pharma Inc. Announces Management Changes

Recent updates

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%

Second quarter 2024 earnings: Revenues miss analyst expectations

HOOKIPA Pharma Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Consensus estimates of losses per share improve by 18%

Price target increased by 8.7% to US$50.00

HOOKIPA Pharma Inc. Announces CFO Changes

HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge

HOOKIPA Pharma Inc Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

HOOKIPA Pharma Inc. Announces Positive Clinical Data to Be Presented At the American Society for Clinical Oncology 2024 Annual Meeting

First quarter 2024 earnings released: EPS: US$0.11 (vs US$0.27 loss in 1Q 2023)

HOOKIPA Pharma Inc. to Report Q1, 2024 Results on May 09, 2024

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

HOOKIPA Pharma Inc., Annual General Meeting, Jun 17, 2024

HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

HOOKIPA Pharma Inc. Announces FDA Clearance of Its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

HOOKIPA Pharma Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

HOOKIPA Pharma Provides Non-Compliance Update

Price target decreased by 11% to US$4.17

HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024

HOOKIPA Pharma Inc. Announces Appointment of Dr. Roman Necina as Chief Operations Officer, Effective January 1, 2024

Hookipa Pharma Announces FDA Clearance of Its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Consensus revenue estimates increase by 14%

Price target decreased by 7.6% to US$4.32

HOOKIPA Pharma Inc. Presents Positive Biomarker and Translational Data on HB-200 Monotherapy At Society for Immunotherapy of Cancer 2023

HOOKIPA Pharma Inc. to Report Q3, 2023 Results on Nov 09, 2023

Hookipa Pharma Inc. Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

HOOKIPA Pharma Inc. Announces Resignation of Christine Baker as Chief Operating Officer, Leaving on January 15, 2024

HOOKIPA Pharma Inc. Announces Management Changes

Consensus revenue estimates fall by 18%

New major risk - Shareholder dilution

Price target increased by 16% to US$5.38

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

HOOKIPA Pharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

HOOKIPA Pharma Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus EPS estimates upgraded to US$1.09 loss

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

HOOKIPA Pharma Inc. to Report Q1, 2023 Results on May 11, 2023

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Less than half of directors are independent

Price target decreased by 18% to US$4.64

Full year 2022 earnings: EPS and revenues exceed analyst expectations

HOOKIPA Pharma Receives A Letter from Nasdaq Regarding Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

HOOKIPA Pharma Appoints Katia Schlienger as Chief Medical Officer and Malte Peters to Board of Directors

Price target decreased to US$5.64

Consensus forecasts updated

Price target increased to US$7.17

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HOOKIPA Pharma Inc. to Report Q3, 2022 Results on Nov 14, 2022

Price target decreased to US$6.29

Consensus revenue estimates increase by 11%

Price target decreased to US$6.29

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HOOKIPA Pharma Inc. to Report Q2, 2022 Results on Aug 11, 2022

Food and Drug Administration Accepts Hookipa’s Investigational New Drug Application for HB-300

HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy

HOOKIPA Pharma Inc.(NasdaqGS:HOOK) dropped from Russell 2000 Dynamic Index

HOOKIPA Pharma Inc. Announces Executive Leadership Changes

HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO

HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommend Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO